Category: United States
-
Federal Circuit dismisses ParkerVision appeal against Qualcomm: Rule 54(b) does not allow partial final judgment on some claims of one patent
The Federal Circuit has held that a patent is a single cause of action, so judgments on receiver claims cannot be appealed while transmitter claims remain pending. ParkerVision’s 15 years of litigation have returned to Florida.
-
Nvidia sued in Eastern District of Texas by PAE holding data center, networking patents originally owned by Avaya
PulseLink Systems is also enforcing former Avaya patents against Hewlett Packard Enterprise and Zoom.
-
Netlist adds new ITC complaint against Micron, Broadcom, Google, and Nvidia; “intends to rely on… Samsung” to prove domestic industry
After settling with Netlist last month, Samsung agreed to provide “certain information… to use in future ITC actions against third parties”.
-
Novo Nordisk signs GLP-1 licensing agreement with China’s Hengrui Pharma
Novo Nordisk and Hengrui Pharma’s agreement, subject to antitrust approval, will allow Novo to obtain exclusive rights to develop, manufacture, and commercialize HRS-1596 globally, excluding mainland China, Hong Kong, Macao, and Taiwan.
-
Via annual Bridge Summit to focus on AI licensing
Via Licensing Alliance’s fourth-ever annual Bridge Summit, due to take place next week, will feature AI infrastructure and data center licensing discussions throughout its conference, as well as licensor meetings dedicated to its newly launched DRAM pool.
-
Jury awards Burford-funded Taction $5.7B against Apple, but verdict appears not too likely to be affirmed; even JMOL appears possible
It will not be easy to defend this record patent damages verdict, given not only its outsized amount but also the deficiencies of the record that Apple has already alleged.
-
Mylan seeks declaratory judgment against Novo Nordisk over newly issued Wegovy patent, aiming to preempt a new Delaware lawsuit
Mylan has asked a Delaware court to declare a newly issued Novo Nordisk Wegovy patent invalid and not infringed, opening a new front in their long-running Hatch-Waxman fight over generic semaglutide.
-
Federal court dismisses Entresto antitrust suit against Novartis: patent listing in Orange Book was proper
Judge Liman held that the U.S. Patent No. 8,101,659 claims the active ingredients on Entresto’s FDA label, so its Orange Book listing was proper, ending a payor’s antitrust case with prejudice.
-
BYD seeks declaratory judgment against First Solar following ITC complaint withdrawal, challenges patent ownership
First Solar claimed it was “recalibrating” its patent enforcement strategy after U.S. President Trump sought to impose tariffs on polysilicon imports from China and elsewhere.